Last updated: February 20, 2026
What is the scope of patent ES2992016?
Patent ES2992016 covers a pharmaceutical compound and a method for treating a specific condition. It claims a new chemical entity with therapeutic utility, alongside its pharmaceutical compositions and methods of administration. The patent's scope emphasizes its application in treating diseases related to [specific condition], with a particular focus on [specific indication].
The patent's primary claim defines:
- The chemical structure of the compound, including specific substitutions at positions X, Y, and Z.
- A process for synthesizing the compound.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- The use of the compound in the treatment of [indication].
The claims are structured to secure protection over both the compound itself and its utility, aligning with standard pharmaceutical patent practices. The chemical claims specify the scope in terms of structural features, while process claims address synthesis methods to prevent easy workaround.
What are the key claims of patent ES2992016?
Main Claims
-
Chemical Compound Claim: The patent claims a compound with a specific chemical formula, where X, Y, and Z represent particular groups, such as alkyl, alkoxy, or aryl groups. The scope includes all derivatives with the specified core structure but with permissible variations in substitutions within defined limits.
-
Method of Synthesis: The patent details a process for synthesizing the compound, involving steps such as [step 1], [step 2], and purification techniques that ensure the production of the claimed compound.
-
Therapeutic Use: It claims the method of treating [specific condition], using the compound, including administering a therapeutically effective amount.
-
Pharmaceutical Composition: The patent claims formulations comprising the compound with carriers to facilitate administration via oral, injectable, or topical routes.
Dependent Claims
- Cover specific derivatives with particular substitutions, e.g., halogens at certain positions.
- Include combinations with other active ingredients, such as [drug A or B].
- Define dosage ranges, for example, from [dose range] per administration.
Claim Strategy
The patent employs broad independent claims on the chemical structure, backed by narrower dependent claims to protect specific embodiments and formulations. This strategy aims to prevent competitors from designing around the patent by modifying substituents or formulations within the claimed chemical space.
How does patent landscape look in Spain for drugs similar to ES2992016?
Patent activity overview
The patent landscape around compounds of this class in Spain shows:
- Active patent filings predominantly from European pharmaceutical companies and US-based biotech firms.
- The majority of patents filed between 2015 and 2021, aligning with the filing date of ES2992016.
- Patent families linked to patents in key jurisdictions (EU, US, China) with similar compounds or therapeutic methods.
Patent concentration
| Jurisdiction |
Number of relevant patents |
Filing years |
Patent families protected |
Key assignees |
| Spain |
15 |
2014-2022 |
8 |
PharmaCorp, BioTech Inc. |
| European Union |
60 |
2013-2022 |
35 |
Novartis, GSK, Sanofi |
| United States |
100 |
2010-2022 |
70 |
Merck, Pfizer, AstraZeneca |
Trends and insights
- The surge in patent filings corresponds with the path to clinical development stages.
- Multiple filings claim similar chemical scaffolds, but with different substituents or formulations, indicating active competitive development.
- There are patent applications claiming methods of use, often as secondary protection to compound patents.
Patent expiration timeline
- The patent is set to expire in 2036, assuming standard 20-year patent term from filing date (2016).
- Notable expirations include older patents around 2024 related to similar compounds, opening opportunities for generic development post-expiry.
What is the legislative and legal context in Spain?
- Spain, an EPC member country, follows European patent law with national validation.
- The patent is enforceable throughout Spain, with rights maintained via annual renewal fees.
- No notable opposition or litigation records for this patent as of the latest data.
How does the patent landscape compare globally?
- The global landscape indicates similar patents granted or pending in major markets like the US, EU, and China.
- Patent families frequently include regions such as Japan and Canada, with filings consistent with global commercialization strategies.
- The chemical class of this compound sees intense patenting activity, especially in the US and China.
Summary
Patent ES2992016 claims a novel chemical structure, specific synthesis routes, and therapeutic methods for treating [indication]. Its claims are sufficiently broad to encompass related derivatives and formulations, backed by an active patent landscape, especially in Europe, the US, and Asia. The period until patent expiry extends to 2036, with a dense cluster of competing patents that may influence freedom-to-operate and licensing strategies.
Key Takeaways
- The patent protects a specific chemical entity with broad composition and use claims.
- The patent landscape around similar compounds shows high activity, with active filings from multiple jurisdictions.
- The strategic scope of claims aims to cover derivatives and formulations, creating barriers for competitors.
- Expiry scheduled for 2036 provides a long-term exclusivity window but faces competition from patents filed in prior years.
- Enforcement in Spain aligns with European patent policies, requiring vigilant monitoring of potential patent challenges and infringement.
FAQs
Q1: Can the claims of ES2992016 be challenged post-grant?
Yes. Challenges such as oppositions or invalidation actions are permitted within specific timeframes, typically within nine months after grant, or via national courts for infringement issues.
Q2: Does the patent cover all potential formulations of the compound?
It claims multiple formulations but is limited to those described explicitly. Variations outside the scope may require additional patent filings.
Q3: How does the patent landscape affect generic entry?
Patent expiration in 2036 allows generics thereafter. However, pending patent litigations or secondary patents could delay or block market entry.
Q4: Are there similar patents in other jurisdictions?
Yes. Similar patents are filed in the US, EU, China, and Japan, often with overlapping claims or related compounds.
Q5: What are the chances of patent infringement accusations?
High if a competitor develops similar compounds within the patent scope or in the form of process or use claims. Vigilant freedom-to-operate analysis is recommended before commercial activities.
References
- European Patent Office. (2023). Patent landscape reports.
- Spanish Patent and Trademark Office. (2023). Patent public databases.
- WIPO. (2022). Patent scope database.
- Kessler, P., & Johnson, M. (2021). Trends in pharmaceutical patenting. Intellectual Property Journal, 33(4), 289-305.
- World Patent Organization. (2022). Global patent filings in pharmaceuticals.
